Advocacy

On June 27, 2019, the Legislature passed HB 696, common-sense legislation to better protect New Hampshire’s older and disabled adults from abuse, neglect and exploitation. The bill, which was the product of bipartisan compromise, will soon be on its way to Governor Sununu’s desk for signature. A diverse group of stakeholders is urging the Governor to sign this important bill into law.

The home of state government is a sacred place.  In New Hampshire, we have the largest state legislative body in the country.  (424 members!)  So, we’re big but what really goes on and how does the legislative process work?

AARP New Hampshire volunteer advocate Guy Chapdelaine offered this testimony at the Senate Finance Committee hearing on May 8 in Manchester.

Doug McNutt, Associate State Director for Advocacy for AARP New Hampshire, offered this testimony at today’s Senate Finance Committee hearing.

AARP New Hampshire volunteer advocates Karen Ulmer Dorsch and Mary Roberge offered this testimony at Tuesday’s Senate Finance Committee Hearing in Concord.

The following is a statement from AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond on the approval of two bills endorsed by AARP: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (H.R. 965) and the Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499).

AARP offers these views on HB1, in today’s public budget hearing.

AARP offers these views in increasing funding to help family caregivers in New Hampshire.

AARP has launched “ Stop Rx Greed,” a nationwide campaign aimed at lowering prescription drug prices.  The goal of AARP’s sustained campaign is to help drive down drug prices for Granite Staters and all Americans by advocating for a variety of legislative, executive, and regulatory actions at both the federal and state level.

Today, AARP released the following statement from Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond. The statement is in response to seven drug company executives’ testimonies given at the Senate Finance Committee hearing, “Drug Pricing in America: A Prescription for Change, Part II.”